

Martedi 9 marzo 2021											
Ora	AREA FORMAZIONE ECM	AULA 1	AULA 2	AULA 3	AULA 4	AULA 5	AULA 6				
10.00-11.00			OPENING CEREMONY Giorgio Racagni, Elena Cattaneo, Michael Spedding								
11.00-11.30			Plenary Lecture Clinical trials between innovation and ethics: what have we learnt in the last 20 years and during COVID-19 - <i>Nicola Magrini</i>								
11.30-13.00			Plenary Round Table Drug policies and future priorities								
13.00-14.00				Bro	eak						
14.00-14.30						Scientific Session					
14.30-15.00		Scientific Session Epigenetic and genetic modulation in substance use disorders Scientific Session	SIF-Farmindustria Symposium Value of pharmaceutical industry for	Scientific Session New possible pharmacological targets for the treatment of obesity and metabolic syndrome	Scientific Session Early synaptic failure: from developmental to age related diseases	(P) ovalution of cancar thorany; are we	Scientific Session Translational research openings for the cure of amyotrophic lateral sclerosis				
15.00-15.30											
15.30-16.00			innovation and sustainability		Scientific Session Targeting purinergic receptors to promote damage resolution and repair in neurodegenerative diseases	Lecture Druggable targets meet oncogenic drivers: opportunities of target-based classification of tumors and the role of institutional Precision Oncology Support Team	Scientific Session Non-coding RNA based strategies in sporadic and familiar neurodegenerative				
16.00-16.30	Scientific Session The circular life of human CD38:	Neurobiology of Post-Traumatic Stress Disorder: from rodents to patients		Scientific Session		Round Table Cardiovascular Prevention: what European Guidelines say and how to	disorders				
16.30-17.00				New trends in hereditary rare channelopathies: complex genetics, phenotype heterogeneity and precision							
17.00-17.30				medicine		apply in Italy					

Il VALORE SCIENTIFICO e l'USO APPROPRIATO del FARMACO



8.30-10.00 Reuropharmocology 1 10.00-10.30 Selentific Session 10.30-11.00 10.30 PCK9: from Biology to Genetics 10 PKH more obligation in PR more obligation of the three XXI century virus: their more general, control and eradication in PKH more obligation in PKH more obligat	Mercoledì 10 marzo 2021										
8.30-10.00 10.00-10.30 10.00-10.30 10.00-10.30 10.00-10.30 10.30-11.00 10.30-11.30 10.00-10.30 10.30-11.00 10.30-11.30 10.30-	Ora	AREA FORMAZIONE ECM	AULA 1	AULA 2	AULA 3	AULA 4	AULA 5	AULA 6	AULA 7		
Scientific Session PCKV9: from Biology to Genetics to Pharmacology Discostination D	8.30-10.00						Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics and Real World	Inflammation Pharmacology and	Oral Communications Pharmacognosy, Phytoterapy and Nutraceuticals 1		
10.30-11.00 to Pharmacology 11.00-11.30 to Pharmacology 11.00-11.30 to Pharmacology 11.30-12.00 to Pharmacology 12.00-13.30 to Pharmacology 13.30-14.30 to Pharmacology 15.00-15.30 to Pharmacology 15.00-15.30 forus On exketamine in treatment resistant depression 15.30-16.00 to Scientific Session 16.30-17.00 to Scientific Session 17.00-17.30 (No disorders much more than 10 to therapeutic and eradication of the imflammatory response in patients with OVID-19 pneumonia unitary of the preparation of the imflammatory response in patients with OVID-19 pneumonia unitary of the preparation of the imflammatory response in patients with OVID-19 pneumonia unitary of the preparation of the imflammatory response in patients with OVID-19 pneumonia unitary of the preparation of the imflammatory response in patients with OVID-19 pneumonia unitary of the preparation of the imflammatory response in patients with OVID-19 pneumonia unitarious devices and new therapeutic source and new therapeutics avenues Scientific Session Novel drugs and therapies for rare genetic pediatric diseases Scientific Session Novel drugs and therapies for rare genetic pediatric diseases Scientific Session Novel drugs and therapies for rare genetic pediatric diseases Scientific Session Novel drugs and therapies for rare genetic pediatric diseases Scientific Session Novel drugs and therapies for rare genetic pediatric diseases Scientific Session Novel drugs and therapies for rare genetic pediatric diseases Scientific Session Novel drugs and therapies for rare genetic pediatric diseases Scientific Session Novel drugs and therapies for rare genetic pediatric diseases Scientific Session Novel drugs and therapies for rare genetic pediatric diseases Scientific Session Novel drugs and therapies for rare genetic pediatric diseases Scient	0.00-10.30				WARNING ON: The value of plasma-	Tackling progression of Multiple Sclerosis:		l .			
Plenary Lecture Vaccines and monoclonals to regain our freedom - Rino Rappuoli Plenary Round Table Anti-COVID vaccines and new therapeutics avenues Break Scientific Session The long road of cannabinoids in epilepsy 15.30-16.00 Scientific Session The long road of cannabinoids in epilepsy 15.30-16.00 Scientific Session Touch Consideration leads to dysfunction: new perspectives for the repeatic intervention in Neurodegenerative Diseases Scientific Session Touch Consideration leads to dysfunction: new perspectives for the repeatic intervention in Neurodegenerative Diseases Scientific Session A new approach to the inflammatory response in patients with COVID-19 pneumonia Scientific Session Touch Touch Touch Touch Countries and monoclonals to regain our freedom - Rino Rappuoli Plenary Round Table Anti-COVID vaccines and new therapeutics avenues Scientific Session When the interaction leads to dysfunction: new perspectives for therapeutic intervention in Neurodegenerative Diseases Induced depression: from genes to hard data to therapy Scientific Session A new approach to the inflammatory response in patients with COVID-19 pneumonia Intercompany Symposium with Round Table On Antimicrobids-Healthcure-related infections sustained by MDR Gram Touch Touch Touch Countries and mew therapeutics avenues Scientific Session Novel drugs and therapies for rare genetic pediatric diseases of value added medicines Scientific Session New development in neuroimmunology Scientific Session Nutraceuticis: clinical efficacy and safety CIN disorders; much more than CIN diso	0.30-11.00	<u> </u>			•			1			
12.00-13.30 12.00-13.30 13.30-14.30 14.30-15.00 15.00-15.30 16.00-16.30 16.00-16.30 17.00-17.30 17.00	1.00-11.30				Coffee	Chat					
13.30-14.30 14.30-15.00 15.00-15.30 16.00-16.30 16.30-17.00 17.00-17.30 18.00-17.30 19.00-17.30 19.00-17.30 10.00	1.30-12.00										
Scientific Session The long road of cannabinoids in epilepsy Scientific Session The long road of cannabinoids in epilepsy Scientific Session Neurodegenerative Diseases Scientific Session New developement in neuroimmunology Scientific Session New developement in neuroimmunology Scientific Session New developement in neuroimmunology Scientific Session Nutraceuticals: clinical efficacy and safety Scientific Session Scientific Session Nutraceuticals: clinical efficacy and safety Scientific Session Scientific Sess	2.00-13.30										
When the interaction leads to dysfunction: new perspectives for therapeutic intervention in Neurodegenerative Diseases induced depression 15.30-16.00 Scientific Session 16.00-16.30 Scientific Session Tocus On esketamine in treatment resistant depression Scientific Session A new approach to the inflammatory response in patients with COVID-19 pneumonia Scientific Session A new approach to the inflammatory response in patients with COVID-19 pneumonia Scientific Session A new approach to the inflammatory response in patients with COVID-19 pneumonia Scientific Session Another interaction leads to dysfunction: new perspectives induced depression: from genes to hard-data to therapy Scientific Session Novel drugs and therapies for rare genetic pediatric diseases Scientific Session Novel drugs and therapies for rare genetic pediatric diseases Scientific Session Novel drugs and therapies for rare genetic pediatric diseases Scientific Session Novel drugs and therapies for rare genetic pediatric diseases Scientific Session New development in neuroimmunology Scientif	3.30-14.30		Break								
15.00-15.30 epilepsy 15.30-16.00 Scientific Session Focus On esketamine in treatment resistant depression 16.30-17.00 Scientific Session 16.30-17.00 Scientific Session CNS disorders: much more than the content of the content	4.30-15.00				Scientific Session			Scientific Session			
Scientific Session Focus On esketamine in treatment resistant depression 16.30-17.00 Scientific Session Focus On esketamine in treatment resistant depression Scientific Session A new approach to the inflammatory response in patients with COVID-19 pneumonia Scientific Session A new approach to the inflammatory response in patients with COVID-19 pneumonia Scientific Session A new approach to the inflammatory response in patients with COVID-19 on Antimicrobials -Healthcare-related infections sustained by MDR Gram Scientific Session New developement in neuroimmunology Scientific Session Nutraceuticals: clinical efficacy and safety Nutraceuticals: clinical efficacy and safety Nutraceuticals: clinical efficacy and safety	5.00-15.30	.1	for therapeutic intervention in	induced depression: from genes to hard-	Novel drugs and therapies for rare	health and innovation, the new frontiers	drivers: the role of Tumor Molecular	Heart failure: anything new on the			
Focus On esketamine in treatment resistant depression 16.30-17.00 Scientific Session A new approach to the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of the inflammatory response in patients with COVID-19 pneumonia No. disorders: much more than the control of	5.30-16.00	Scientific Session	Neurodegenerative Diseases	uulu lo iliciupy		or value added illedicilles	Dodias iii i iecisioii olicology				
16.30-17.00 Scientific Session ONS disorders: much more than the substance of the art and perspectives in infections sustained by MDR Gram Scientific Session Nutraceuticals: clinical efficacy and safety ONS disorders: much more than the substance of the art and perspectives in infections sustained by MDR Gram Nutraceuticals: clinical efficacy and safety cancer pharmacology (II) Scientific Session Nutraceuticals: clinical efficacy and safety cancer pharmacology (II)	6.00-16.30	Focus On esketamine in treatment	A new approach to the inflammatory			_	Scientific Session	Scientific Session			
infections sustained by MDR Gram Notracevitals: clinical efficacy and safety cancer pharmacology (II)	6.30-17.00	Scientific Session			1						
neurons negative bacteria	7.00-17.30	CNS disorders: much more than		infections sustained by MDR Gram negative bacteria		INUTFACEUTICALS: CHINICAL ETTICACY AND SAFETY					
17.30-18.00 Round Table	7.30-18.00	110010113	Round Table								
18.00-18.30 Narcolepsy and impact on quality of life, how to recognize and treat it	8.00-18.30										

Il VALORE SCIENTIFICO e l'USO APPROPRIATO del FARMACO



Giovedì 11 marzo 2021										
Ora	AREA FORMAZIONE ECM	AULA 1	AULA 2	AULA 3	AULA 4	AULA 5	AULA 6	AULA 7		
8.30-10.00		Oral Communications Neuropharmacology 2	Oral Communications Sensitive windows of vulnerability for cannabis use on brain development	Oral Communications Pharmacology of Nutritional Disorders	Oral Communications Basic and Clinical Research 2	Oral Communications Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics and Real World Evidence 2	Oral Communications Cancer Pharmacology 2	Oral Communications Toxicology		
10.00-10.30	Scientific Section	Cciontific Coccion		Caiontific Coccion						
10.30-11.00	Scientific Session The role of Real World Evidence in optimizing the management of chronic diseases	Scientific Session Substance use disorder across life: from neurobiological mechanisms to new pharmacological treatments	Scientific Session The certification in Pharmacology: the Italian way	Scientific Session Extended Release Calcifediol: a combined approach to the Secondary Hyperparathyroidism treatment	Scientific Session Precision medicine and pharmacological treatment of psychiatric disorders		Lecture An alternative perspective in approaching Rare Disease: the complement involvement			
11.00-11.30			Coffee Chat							
11.30-12.00		Plenary Lecture University and Research - <i>Gaetano Manfredi</i>								
12.00-13.30		Plenary Round Table The University and Life Science Research: what's next?								
13.30-14.30		Break								
14.30-15.00	Scientific Session	Lecture Adherence therapy with antidepressants		Scientific Session		Scientific Session New targets for pain eradication	Round Table SIF-Assobiotec Clinical trials in Italy: focus on			
15.00-15.30	The value of research in rare	Scientific Session	Scientific Session	Frontiers in Immunomodulation	Scientific Session Pharmacology Teaching: pitfalls and		advanced therapies medicinal products			
15.30-16.00	diseases in the pandemic era	Gut microbiota-brain-immune axis: emerging evidence for a role in	The role of Real-World Evidence for the holistic health management and			Scientific Session				
16.00-16.30		neurological conditions	research: The SIF -RWE Consensus Document		opportunities	Strategies for the therapy of visceral hypersensitivity				
16.30-17.00	Scientific Session FOCUS ON Multiple Sclerosis: The right therapy in the right time		DOCUMBIN	Scientific Session New possible pharmacological targets for the treatment of eating disorders		Scientific Session Pain and Opioids: from preclinical news to clinical perspectives Scientific Session Pharmacogenetics in person therapy: the impact of big d				
17.00-17.30							artificial intelligence			
17.30-18.00										



				Ver	ierdi 12 marzo 2021						
	Ora	AREA FORMAZIONE ECM	AULA 1	AULA 2	AULA 3	AULA 4	AULA 5	AULA 6			
	8.30-10.00		Oral Communications Neuropharmacology 3	Oral Communications Immunometabolism	Oral Communications Pharmacology of Rare Disease	Oral Communications Basic and Clinical Research 3	Oral Communications Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics and Real World Evidence 3	Oral Communications Personalized Medicine and Advanced Therapies			
	10.00-10.30						Scientific Session				
	10.30-11.00	Lecture Understanding the neurobiology in Alzheimer's disease: from beta- amyloid and beyond		Scientific Session Therapeutic management of the main neuromuscular diseases	Scientific Session Advanced Therapies for Ocular Rare Diseases	Lecture Multifactorial inertia as a barrier to the use of pharmacological innovation in diabetes	Innovative medicines in oncology: how to guarantee the recognition of value and rapid access for patients				
	11.00-11.30			Coffee Chat							
	11.30-12.00			Plenary Lecture Transformative genetic and cellular therapy - <i>Franco Locatelli</i>							
	12.00-13.30										
	13.30-14.30				Bred	nk					
	14.30-15.00	Scientific Session Innovation of the Science &					Lecture New pharmacological perspective for the treatment of diffuse large cell lymphoma				
	15.00-15.30	Regulation worlds: transformative therapies and paradigm shifts in the	Scientific Session New insights in Autism Spectrum Disorders: from basic science to novel therapeutic approaches	Round Table Pharmacological evolution between efficacy and sustainability		Scientific Session The role of Real-World Evidence in healthcare emergency for informed drug regulatory decision making	Lecture Innovative therapies for treating advanced or unresectable hepatocellular carcinoma (HCC): from studies to clinical practice	Scientific Session Central and peripheral redox dysregulation and inflammation in neuropsychiatric disorders: from molecular targets to nove therapeutic opportunities			
	15.30-16.00	New frontiers in cardiovascular	upprouches		nover international continuous	uccision muking					
	16.00-16.30						Scientific Session State of the art and perspectives in cancer pharmacology	Round Table			
***	16.30-17.00				Scientific Session	ic Session Round Table		Preclinical animal research: do we meet EU standards?			
	17.00-17.30				Pharmacology and physio-complex products: the case of substance-based medical devices			Sidiladi us:			
	17.30-18.00				THE CASE OF SUBSTAILCE-DASEA HIEACOL AEVICES						



	Sabato 13 marzo 2021										
Ora	AREA FORMAZIONE ECM	AULA 1	AULA 1 AULA 2 AULA 3 AULA 4 AULA 5								
8.30-10.00		Oral Communications Pharmacognosy, Phytoterapy and Nutraceuticals 2	Oral Communications Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics and Real World Evidence 4	Oral Communications Basic and Clinical Research 4	Oral Communications Pharmacogenetics	Oral Communications Gender and Pediatric Pharmacology	Oral Communications Pain Pharmacology and Pathological Addiction				
10.00-11.00	Scientific Session		Scientific Session	Scientific Session	Scientific Session Gender pharmacology and SARS-CoV-2: a call for action	Scientific Session Tumor molecular board for cancer diagnosis and therapy: rationale and practice					
11.00-11.30	Pharmacological effects and genotoxic properties of synthetic psychoactive substances		From medication review to deprescribing: new strategies to improve a rationale use of medicine	Drugs in the environment: risk assessment, regulatory landscape and future challenges							
11.30-12.00		Plenary Lecture Inflammation, a metanarrative from cancer to COVID-19 - <i>Alberto Mantovani</i>									
12.00-13.00		CONCLUSIONS AND AWARDS									

Il VALORE SCIENTIFICO e l'USO APPROPRIATO del FARMACO

